The FDA has reinforced safety warnings for Kybella (deoxycholic acid), the injectable fat-dissolving treatment approved in 2015 for submental fat (double chin), citing "newly identified risks" from post-market surveillance. The updated label now explicitly warns that Kybella should not be used outside the chin area — a restriction that existed before but is now elevated to the warnings and precautions section — and notes that some injection-site nodules and masses may not resolve on their own and may require medical intervention.

The agency's review of its Adverse Event Monitoring System and medical literature uncovered troubling patterns of harm from off-label use. Serious events included blurred or reduced vision when injected near the eyes, and facial paresis and paresthesia from nerve injury. Unresolved tissue growths — some present for an average of ~5 months — were also flagged.

By the Numbers:

• 129 cases of adverse events linked to off-label Kybella injections outside the submental area
• 117 cases of unresolved nodules (≤3 cm) or masses (>3 cm), persisting a mean of ~5 months
• 13% of clinical trial participants experienced nodule formation
• 4% of patients in the 2015 advisory committee trials experienced marginal mandibular nerve injury (vs. 1% placebo)

Why it matters: With Kybella widely used off-label across the face and body, this label update is a critical signal for aesthetic practitioners. Clinicians should review updated prescribing information before use and counsel patients to seek prompt care if they notice nerve symptoms, swallowing difficulties, or unusual injection-site reactions.